GlassScriptPhysician profile
Vincent C Schooler
NPI 1467479204
$5,038.08
in general payments reported to CMS, 2019-2025
35 companies · $1,728 in 2025
The $1,728 reported for 2025 was more than what 75% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $936 · 2020: $292 · 2021: $167 · 2022: $358 · 2023: $645 · 2024: $913 · 2025: $1,728.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,202 · Education: $84.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,201.76 |
| Education | $84.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,155.22 | 2019-2025 | Linzess, Viberzi, Rinvoq |
| Janssen Biotech, INC. | $593.18 | 2020-2025 | Tremfya, Stelara, Simponi Aria |
| Pfizer INC. | $464.78 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $343.04 | 2019-2025 | Xifaxan, Trulance, Relistor |
| Takeda Pharmaceuticals U.S.A., INC. | $285.64 | 2019-2025 | Eohilia, Entyvio |
| Aimmune Therapeutics, INC. | $273.61 | 2024-2025 | Zenpep |
| Ardelyx, INC. | $246.00 | 2023-2025 | Ibsrela |
| Celgene Corporation | $163.30 | 2022-2023 | Zeposia |
| Ucb, INC. | $156.09 | 2019-2020 | |
| Regeneron Healthcare Solutions, INC. | $120.11 | 2022-2025 | Dupixent |
| Merck Sharp & Dohme LLC | $120.08 | 2019-2024 | Dificid |
| Amgen INC. | $118.87 | 2022-2025 | Uplizna |
| Ironwood Pharmaceuticals, INC | $111.35 | 2019-2024 | Linzess |
| Gilead Sciences, INC. | $103.53 | 2019-2025 | |
| Madrigal Pharmaceuticals | $95.75 | 2025 | Rezdiffra |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intercept Pharmaceuticals, INC. | $81.89 | 2019-2023 | Ocaliva |
| Nestle Healthcare Nutrition INC. | $72.91 | 2021-2023 | |
| Shionogi INC | $63.48 | 2019 | |
| Novo Nordisk INC | $62.33 | 2024-2025 | Wegovy |
| Daiichi Sankyo INC. | $49.39 | 2024-2025 | Injectafer |
| Boehringer Ingelheim Pharmaceuticals, INC. | $44.46 | 2023-2024 | Cyltezo |
| Boston Scientific Corporation | $38.27 | 2023 | Watchman Flx |
| Shire North American Group INC | $38.18 | 2019 | |
| Phathom Pharmaceuticals, INC. | $34.48 | 2025 | Voquezna |
| Redhill Biopharma INC. | $27.35 | 2022-2023 | Aemcolo, Talicia, Movantik |
| Celltrion USA INC. | $26.77 | 2024 | Vegzelma |
| Genzyme Corporation | $24.30 | 2024 | |
| Curium US LLC | $19.46 | 2025 | Detectnet |
| Lilly USA, LLC | $18.54 | 2025 | Omvoh |
| Sandoz INC. | $18.42 | 2024 | Hyrimoz |
| Braintree Laboratories, INC. | $15.24 | 2023 | Sutab |
| Mallinckrodt Hospital Products INC. | $14.37 | 2025 | Terlivaz |
| Fresenius Kabi USA, LLC | $13.26 | 2023 | Idacio |
| Intra-Sana Laboratories | $12.86 | 2021 | |
| Ferring Pharmaceuticals INC. | $11.57 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vincent Schooler listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.